Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States
Antepartum Care
Special Situations - HIV/Hepatitis B Virus Coinfection
(Last updated:9/14/2011)
Panel’s Recommendations:
• Screening for hepatitis B virus (HBV) infection is recommended for all pregnant women who have not been screened during the current pregnancy (AII).
• The HBV vaccine series should be administered to pregnant women who screen negative for hepatitis B (i.e., hepatitis B surface antigen negative, hepatitis B core antibody negative, and hepatitis B surface antibody negative) (AII).
• Pregnant women with chronic HBV infection should be screened for antibodies to hepatitis A virus (HAV), and those who screen negative should receive the HAV vaccine series (AII).
• Interferon alfa and pegylated interferon alfa are not recommended during pregnancy (AIII).
• The management of HIV/HBV coinfection in pregnancy is complex and consultation with an expert in HIV and HBV is strongly recommended (AIII).
• All pregnant women with HIV/HBV coinfection should receive a combination antiretroviral (ARV) drug regimen, including a dual nucleoside reverse transcriptase inhibitor (NRTI)/nucleotide analogue reverse transcriptase inhibitor (NtRTI) backbone with two drugs active against both HIV and HBV (AII). Tenofovir plus lamivudine or emtricitabine is the preferred dual NRTI/NtRTI backbone of a combination antepartum ARV regimen in HIV/HBV-coinfected pregnant women (AI).
• If ARV drugs are discontinued postpartum in women with HIV/HBV coinfection, frequent monitoring of liver function tests for potential exacerbation of HBV infection is recommended, with prompt reinitiation of treatment for both HIV and HBV if a flare is suspected (BIII).
• Pregnant women with HIV/HBV coinfection receiving ARV drugs should be counseled about the signs and symptoms of liver toxicity, and liver transaminases should be assessed 1 month following initiation of ARV drugs and at least every 3 months thereafter (BIII).
• Within 12 hours of birth, infants born to women with HBV infection should receive hepatitis B immune globulin (HBIG) and the first dose of the HBV vaccine series. The second and third doses of vaccine should be administered at ages 1 and 6 months, respectively (AI). |
For additional information on hepatitis B and HIV, see Hepatitis B (HBV)/HIV Coinfection in Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (http://AIDSInfo.nih.gov) [1] and Hepatitis B Virus Infection in the Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, Recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America [2].
All HIV-infected pregnant women should be screened for hepatitis A, B, and C. The management of HIV/HBVcoinfection in pregnancy is complex and consultation with an expert in HIV and HBV infection is strongly recommended. HIV-infected women who are found to have chronic HBV infection on the basis of persistent hepatitis B surface antigenemia for at least 6 months and who are hepatitis A immunoglobulin G (IgG) negative should receive the HAV vaccine series because of the added risk of acute hepatitis A in persons with chronic viral hepatitis.
HIV-infected pregnant women who test negative for hepatitis B surface antibody and hepatitis B surface antigen should receive the HBV vaccine series. A positive test for hepatitis B core antibody alone can be a false-positive result, or it may signify past exposure with subsequent loss of hepatitis B surface antibody, or “occult” HBV infection, which can be confirmed by detection of HBV DNA [3-4]. The clinical significance of isolated hepatitis B core antibody is unknown [5-6]. Some experts recommend that HIV-infected persons with hepatitis B core antibody alone should be tested for HBV DNA before vaccination for HBV or before treatment or prophylaxis with ARV drugs is initiated because of the risk of a paradoxical exacerbation of HBV and the occurrence of immune reconstitution inflammatory syndrome (IRIS) [2].
An ARV regimen that includes drugs active against both HIV and HBV is recommended for all individuals with HIV/HBV coinfection who require HBV treatment or who are starting ARV drugs, including pregnant women. Initiation of an ARV regimen that does not include anti-HBV drugs may be associated with reactivation of HBV and development of IRIS; IRIS-related flare of HBV activity during pregnancy can occur even among women with relatively high CD4 cell counts at the time of ARV initiation. In addition, use of ARV drugs with anti-HBV activity during pregnancy lowers HBV viremia, potentially increasing the efficacy of neonatal HBIG and hepatitis B vaccine in prevention of perinatal transmission of HBV. High maternal HBV DNA levels are strongly correlated with perinatal HBV transmission and with failures of HBV passive-active immunoprophylaxis [7-9]. Several small studies suggest that lamivudine or telbivudine may reduce the risk of perinatal transmission of HBV if given during the third trimester to HBV-infected, HIV-seronegative women with high HBV DNA viremia [10-13]. Although a high HBV viral load clearly is important, it is, however, not the only factor predisposing to failure of prophylaxis [14].
Because lamivudine, tenofovir, and emtricitabine have activity against both HIV and HBV, the recommended dual-NRTI/NtRTI backbone for HIV/HBV-coinfected individuals, including pregnant women, is tenofovir/emtricitabine or tenofovir/lamivudine. Lamivudine has been extensively studied and is recommended for use in pregnancy (Table 5). The Antiretroviral Pregnancy Registry includes reports on the outcomes of 3,864 pregnancies that involved administration of lamivudine in the first trimester and there is no indication that the exposure was associated with an increased risk of birth defects [15]. Similarly, no increase in birth defects has been noted in 641 cases of first-trimester exposure to emtricitabine, which is an alternative NRTI for use in pregnancy (Table 5). Tenofovir is not teratogenic in animals, but reversible bone changes at high doses have been seen in multiple animal species. A total of 1,092 cases of first-trimester exposure have been reported to the Antiretroviral Pregnancy Registry, with no increase in birth defects noted [15]. Although tenofovir is recommended as an alternative NtRTI during pregnancy for ARV-naive women, it is a preferred NtRTI in women with HIV/HBV coinfection (Table 5).
Several other antivirals with activity against HBV, including entecavir, adefovir, and telbivudine, have had minimal evaluation in pregnancy. Entecavir is associated with skeletal anomalies in rats and rabbits but only at doses high enough to cause toxicity to the mother. No data are available on use of entecavir and adefovir in human pregnancy. Telbivudine was given to 95 HBV-positive, HIV-negative women during the third trimester and was well tolerated [13]. Each of these anti-HBV drugs should be administered only in addition to a fully suppressive regimen for HIV. Because these other anti-HBV drugs also have weak activity against HIV, they may select for anti-HIV drug resistance in the absence of a fully suppressive ARV regimen as well as potential cross resistance to other ARV drugs. (Entecavir, for example, can select for the M184V mutation, which confers HIV resistance to lamivudine and emtricitabine.) These drugs should be used during pregnancy only if the preferred drugs are not appropriate in specific cases. Cases of exposure during pregnancy to any of the ARV drugs and HBV drugs listed should be reported to the Antiretroviral Pregnancy Registry (800-258-4263; http://www.apregistry.com).
Interferon alfa and pegylated interferon alfa are not recommended for use in pregnancy and should be used only if the potential benefits outweigh the potential risks. Although interferons are not teratogenic, they are abortifacient at high doses in monkeys and should not be used in pregnant women because of the direct antigrowth and antiproliferative effects of these agents [16].
Following initiation of ARV drugs, an elevation in hepatic enzymes can occur in HIV/HBV-coinfected women—particularly those with low CD cell counts at the time of treatment initiation—as a result of an immune-mediated flare in HBV disease triggered by immune reconstitution with effective HIV therapy. HBV infection also can increase hepatotoxic risk of certain ARV drugs, specifically protease inhibitors (PIs) and nevirapine. Pregnant women with HIV/HBVcoinfection should be counseled about signs and symptoms of liver toxicity, and transaminases should be assessed 1 month following initiation of ARV drugs and at least every 3 months thereafter. If hepatic toxicity occurs, it may be necessary to consider substituting a less hepatotoxic regimen or, if clinical symptoms or significant elevations of transaminases occur, drugs may need to be temporarily discontinued. Differentiating between a flare in HBV disease due to immune reconstitution and drug toxicity often can be difficult, and consultation with an expert in HIV and HBV coinfection is strongly recommended. Because tenofovir has potential to cause renal toxicity, kidney function also should be monitored regularly in women receiving this drug, based on toxicity seen in nonpregnant adults.
Following delivery, considerations regarding continuation of the ARV drug regimen are the same as for other nonpregnant individuals (see General Principles Regarding Use of Antiretroviral Drugs During Pregnancy). Discontinuation of agents with anti-HBV activity may be associated with hepatocellular damage resulting from reactivation of HBV. Frequent monitoring of liver function tests for potential HBV flare is recommended in women with HIV/HBV coinfection whose ARV drugs are discontinued postpartum, with prompt reinitiation of treatment for both HIV and HBV if a flare is suspected.
Within 12 hours of birth, all infants born to mothers with chronic HBV infection should receive HBIG and the first dose of the HBV vaccination series. The second and third doses of vaccine should be administered at ages 1 and 6 months, respectively. This regimen is >95% effective in preventing HBV infection in these infants.
References
1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2011:1-174. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
2. Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE201-204.
3. Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol. 2000 Dec;62(4):450-455.
4. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis. 1998 Jan;17(1):6-13.
5. Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis. 1998 Apr;26(4):895-897.
6. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology. 1988 Jul-Aug;8(4):766-770.
7. del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol. 1994 Apr;20(4):483-486.
8. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis. 1998 Jul;27(1):100-106.
9. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009 May 4;190(9):489-492.
10. van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol. 2000 Jun;32(6):1040-1041.
11. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003 Jul;10(4):294-297.
12. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010 Jul;116(1):147-159.
13. Han G, Zhao W, Cao M, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus to the infants. Paper presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD); Oct 29-Nov 2, 1010; Boston, MA.
14. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet. 2002 Apr 27;359(9316):1488-1489.
15. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989 - 31 Jan 2011. Wilmington, NC: Registry Coordinating Center; 2011. Available from URL: http://www.APRegistry.com.
16. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005 Sep 27;65(6):807-811.